Document Detail

First report on safety and efficacy of hetastarch solution for initial fluid resuscitation at a level 1 trauma center.
MedLine Citation:
PMID:  20421069     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: For logistics, the US Army recommends Hextend (Hospira; 6% hetastarch in buffered electrolyte, HET) for battlefield resuscitation. To support this practice, there are laboratory data, but none in humans. To test the hypothesis that HET is safe and effective in trauma, we reviewed our first 6 months of use at a civilian level 1 trauma center. STUDY DESIGN: From June 2008 to December 2008, trauma patients received standard of care (SOC) +/- 500 to 1,000 mL of HET within 2 hours of admission at surgeon discretion. Each case was reviewed, with waiver of consent. RESULTS: There were 1,714 admissions; 805 received HET and 909 did not. With HET versus SOC, overall mortality was 5.2% versus 8.9% (p = 0.0035) by univariate analysis. Results were similar after penetrating injury only (p = 0.0016) and in those with severe injury, defined by Glasgow Coma Scale <9 (p = 0.0013) or Injury Severity Score >26 (p = 0.0142). After HET, more patients required ICU admission (40.9% vs. 34.5%; p = 0.0334) and transfusions of blood (34.4% vs. 20.2%; p = 0.0014) or plasma (20.7% vs. 12.2%; p = 0.0251), but there were no treatment-related differences in prothrombin time or partial thromboplastin time. The 24-hour urine outputs and requirements for blood, plasma, and other fluids were similar. However, increased early deaths with SOC implicate possible selection bias. If that factor was controlled for with multivariate analysis, the same trends were present, but the apparent treatment effects of HET were no longer statistically significant. CONCLUSIONS: In the first trial to date in hemodynamically unstable trauma patients, and the largest trial to date in any population of surgical patients, initial resuscitation with HET was associated with reduced mortality and no obvious coagulopathy. A randomized blinded trial is necessary before these results can be accepted with confidence.
Michael P Ogilvie; Bruno M T Pereira; Mark G McKenney; Paul J McMahon; Ronald J Manning; Nicholas Namias; Alan S Livingstone; Carl I Schulman; Kenneth G Proctor
Related Documents :
9261779 - Effect of timing of stabilization on length of stay and medical complications following...
15142699 - Carpal tunnel decompression. is lengthening of the flexor retinaculum better than simpl...
3967409 - Low-velocity gunshot wounds in police officers.
6722419 - Patello-femoral arthralgia in athletes attending a sports injury clinic.
2758189 - Severe traumatic brain lesions in sweden. part 2: impact of aggressive neurosurgical in...
24887819 - Double-valve surgery in shprintzen-goldberg syndrome.
15045129 - Treatment with anticoagulants in cerebral events (trace).
8053389 - Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the trea...
17378719 - Labor induction in preeclampsia: is misoprostol more effective than dinoprostone?
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of the American College of Surgeons     Volume:  210     ISSN:  1879-1190     ISO Abbreviation:  J. Am. Coll. Surg.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-27     Completed Date:  2010-05-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431305     Medline TA:  J Am Coll Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  870-80, 880-2     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
Daughtry Family Department of Surgery, Divisions of Trauma and Surgical Critical Care, University of Miami Miller School of Medicine, Miami, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cohort Studies
Hetastarch / therapeutic use*
Hospital Mortality
Middle Aged
Pharmaceutical Solutions
Plasma Substitutes / therapeutic use*
Retrospective Studies
Survival Rate
Trauma Centers*
Trauma Severity Indices
Treatment Outcome
Wounds and Injuries / complications,  mortality*,  therapy*
Young Adult
Reg. No./Substance:
0/Pharmaceutical Solutions; 0/Plasma Substitutes; 9005-27-0/Hetastarch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lactate is a better predictor than systolic blood pressure for determining blood requirement and mor...
Next Document:  A rare anterior sacral osteochondroma presenting as sciatica in an adult: a case report and review o...